Encephalitis is an inflammation of the brain tissue. There are two main types of encephalitis: primary and secondary. Primary encephalitis occurs when a virus directly infects the brain and spinal cord. Secondary encephalitis occurs when an infection starts elsewhere in the body and then travels to your brain
Rise in number of patient in hospitals suffering from chronic infections such as tick-borne encephalitis and rabies encephalitis and increasing investment by major players for development of new drugs are major factors expected to drive the growth of the global encephalitis vaccines market. There is increase in patients suffering from encephalitis. According to a UNICEF report, globally, Japanese Encephalitis causes an estimated 70,000 cases and 20,400 deaths per year, and has a case fatality rate of between 20-30%. It is the leading cause of viral encephalitis in Asia and the Western Pacific. Researchers are spending high in the development of advanced diagnosis methods and advanced solutions in order to cure infections. Major players spending high in R&D activities in collaboration with government they are focused on delivering vaccine to patients. Changing government regulations and increasing clinical trial & drugs approvals from regulatory bodies is expected to impact the growth of target market. In 2021, U.S. Food and Drug Administration (FDA) accepted for priority review the Pfizer Inc. companies Biologics License Application (BLA) for TicoVac, its tick-borne encephalitis (TBE) vaccine for active immunization to prevent TBE in individuals 1 year of age and older. Increasing players focus in enhancing the business through strategic partnerships and agreements this is expected to support the growth of the encephalitis vaccines market.
In 2020, Valneva SE, a specialty vaccine company, signed a strategic partnership with Bavarian Nordic A/S. The partnership was focused on marketing and distribution of their commercial products. Under the partnership Valneva will commercialize Bavarian Nordic’s marketed vaccines leveraging its commercial infrastructure in Canada, UK, France and Austria.
In 2020, Bavarian Nordic, a biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines initiation of full commercial operations in Germany for Encepur® (Tick-Borne Encephalitis vaccine). This is expected to help the company to enhance the customer base and increase the revenue share.
Government is increasing the awareness among the consumers related to the vaccines; through various campaigns, the government is facilitating the vaccination. In 2015, Laos launched nationwide Japanese encephalitis (JE) campaign aimed at reaching 1.5 million children between the ages of one and 15 years. Factors such as high cost of R&D activities and stringent government regulations related to product approval are expected to hamper the growth of global encephalitis vaccines market. In addition, side-effect of vaccine is expected to limit its adoption further challenging the growth of target market. However, increasing investment by major players for development of effective product and rising government initiatives related to vaccination program are factors expected to create new opportunities for players operating in the encephalitis vaccines market over the forecast period. In addition, increasing strategic partnership between regional and international players is expected to support the revenue transaction of target market.
Segment Analysis by Region
The market in Asia Pacific is expected to account for major revenue share in the global encephalitis vaccines market due to high patient pool suffering from chronic infection. In addition, increasing government initiatives for awareness among consumers and high spending on development of healthcare infrastructure for R&D activities are aspects responsible for regional market growth. Favorable business policies by the government and emergence of mid-size enterprises with innovative drugs are factors expected to support the regional market growth.
The global encephalitis vaccines market is highly competitive due to the presence of many players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
Encephalitis Vaccines Market Segment Analysis, 2019
The global encephalitis vaccines market is segmented into vaccination type, type of indications, and end use. The vaccination type segment is bifurcated into mouse brain-derived, inactivated vaccine, cell culture-derived, inactivated vaccine, and cell culture-derived, live attenuated vaccine. Among vaccination type the cell culture-derived inactivated vaccine segment is expected to account for a noticeable revenue share in the global encephalitis vaccines market. The end use segment is divided into child and adult and among end use the child segment is expected to witness faster growth in target market. The players profiled in the report are Valneva SE., Bharat Biotech, BIKEN, China National Pharmaceutical Group, Liaoning Cheng Bio Co., Ltd., GlaxoSmithKline Plc, Sanofi Pasteur, Tiantan Biological Product, and Zhejiang Tianyuan Bio-Pharmaceutical.
Market By Vaccination Type
Mouse Brain-Derived, Inactivated Vaccine
Cell Culture-Derived, Inactivated Vaccine
Cell Culture-Derived, Live Attenuated Vaccine
Market By Type of Indications
Market By End Use
Market By Geography
• Rest of Europe
• South Korea
• Rest of Asia-Pacific
• Rest of Latin America
Middle East & Africa
• South Africa
• Rest of Middle East & Africa
Rise in number of patient in hospitals suffering from chronic infections such as tick-borne encephalitis and rabies encephalitis and increasing investment by major players for development of new drugs are major factors expected to drive the growth of global encephalitis vaccines market.
In type of vaccination the cell culture-derived, inactivated vaccine segment is growing at faster pace.
In the global market the Asia Pacific region is expected to grow faster.
Some of the players considered in the report scope are Valneva SE., Bharat Biotech, BIKEN, China National Pharmaceutical Group, Liaoning Cheng Bio Co., Ltd., and Glaxosmithkline Plc.
The Asia Pacific is expected to account for major revenue share in the global market.
In end-user the child segment is growing at faster pace.
Factors such as high cost of R&D activities and stringent government regulations related to product approval are expected to hamper the growth of global encephalitis vaccines market.